Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.51 |
| ▸ | PRKDC | P78527 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 12/20 | 0.50 |
| ▸ | LCK | P06239 | 6/20 | 0.50 |
| ▸ | SRC | P12931 | 6/20 | 0.50 |
| ▸ | TEK | Q02763 | 5/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 9/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22381516 | 0.89 | PI4KB (0.41) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL20058786 | 0.87 | PIK3CB (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL21758960 | 0.84 | ADORA2A (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL26357318 | 0.81 | PIK3CD (0.37) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL2618932 | 0.81 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL24258000 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1783992 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL6363939 | 0.80 | KDR (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL408629 | 0.80 | KDR (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL870102 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-9173893-B2 | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | COCRYSTAL PHARMA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015077360-A2 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2013009735-A1 | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | PIK3CD 912/4885PIK3CA 908/4885PIK3CB 1190/4885 |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | ZC3HAV1, HAVCR2, NSUN2 | PIK3CD 4866/4885PIK3CA 4360/4885PIK3CB 4818/4885 |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | PIK3CD 533/4885PIK3CA 330/4885PIK3CB 418/4885 |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | PIK3CD 218/4885PIK3CA 40/4885PIK3CB 202/4885 |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | PIK3CD 218/4885PIK3CA 40/4885PIK3CB 202/4885 |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | PIK3CD 786/4885PIK3CA 232/4885PIK3CB 691/4885 |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, GSTO1 | PIK3CD 561/4885PIK3CA 354/4885PIK3CB 455/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | PIK3CD 2211/4885PIK3CA 2152/4885PIK3CB 2065/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | PIK3CD 786/4885PIK3CA 232/4885PIK3CB 691/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | PIK3CD 2117/4885PIK3CA 2807/4885PIK3CB 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.